

REMARKS

Claims 1 - 38 are presented in this application. In this amendment, claims 28-30, 33, 34, 36, 37 have been amended, claims 1-25 and 27 have been canceled, and claims 39 - 42 have been added.

The specification has been amended for purposes of adding the priority information. An Abstract has been added on a separate sheet of paper as required by US practice. Claims 1-25 and 27 have been canceled, and claims 39-42 have been added in order to more particularly recite the claimed compound, including salts, solvates, and pharmacologically functional derivatives thereof. Support for the amendments and additions is provided in Example 10, originally-filed claim 26, and generally in the originally-filed specification. Claims 28-30, 33, 34, 36, and 37 have been amended to eliminate multiple dependencies in accordance with U.S. practice. No new matter has been added.

It is respectfully requested that the instant application, with the claims as submitted in this amendment, be examined. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


J. Scott Young
Attorney for Applicant
Registration No. 45,582

Date: 20 JAN 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8160
Facsimile: 919-483-7988